ACTA1 and pulmonary fibrosis: In 2012, a study revealed that NAC treatment reversed lysyl oxidase activity to normal levels and increased GSH levels in the lung of bleomycin-induced rats, inhibiting TGF-β1 and α-SMA expression, thus attenuating pulmonary fibrosis (Li et al., 2012).